Biomedical Technology Program

生物医学技术（BTP） 项目总结/摘要 生物医学技术计划（BTP）的中心主题是建立新的技术， 预防和/或减少UC Davis综合癌症中癌症负担的计算方法 中心（UCDCCC）集水区和超越。该计划汇集了工程师，物理科学家， 以及与医学院（SOM）的主要临床研究人员合作的应用物理学家， 兽医学院（SVM）的目标是翻译新的或适应的技术，以提高 癌症检测、诊断和治疗。BTP有四个具体目标，包括广泛的技术 在项目中发现的专业知识。目的1是发展和验证放射诊断和治疗 技术.目标2是开发和验证光学光谱和成像技术（生物光子学）。 目标3是开发用于转化和临床应用的分子和细胞技术。目标4： 开发和验证计算方法和人工智能（AI）技术。Laura Marcu，博士 （生物医学工程）和Ramsey Badawi博士（放射科学）是BTP的共同领导人。的 该计划的研究组合包括广泛的技术和计算方法，从 与PET和CT相关的变革性发展（包括开发世界上第一个全身 PET扫描仪），并建立荧光寿命成像作为术中组织的一种手段 表征，以开发用于成像和治疗的新型治疗诊断剂，并开发强大的神经 网络和其他人工智能（AI）技术来改善癌症成像。BTP有21个正式成员 来自加州大学戴维斯分校的三所学校/学院和七个系。BTP的癌症相关资金总额为960万美元 年度直接成本，包括890万美元的同行评审和460万美元的NCI资金。的总数 出版物为313种，其中22%为计划内出版物，42%为计划间出版物，46%为多机构出版物， 15%发表在高影响力期刊上。作为一个强大的计划，有几项技术进入临床 实施或评估，UCDCCC已部署措施，以确保技术发展， 临床翻译继续。这包括提供机构支持，以维持强有力的跨学科论坛， 为BTP提供可自由支配的资金支持，使其领导层有能力支持试点项目 这将继续该计划的变革性影响。

BIOMEDICAL TECHNOLOGY PROGRAM (BTP) PROJECT SUMMARY/ABSTRACT The central theme of the Biomedical Technology Program (BTP) is to establish novel technologies and computational methods to prevent and/or reduce the cancer burden in the UC Davis Comprehensive Cancer Center (UCDCCC) catchment area and beyond. The Program brings together engineers, physical scientists, and applied physicists who collaborate with key clinical investigators in the School of Medicine (SOM) and School of Veterinary Medicine (SVM) with the goal of translating new or adapted technologies to improve cancer detection, diagnosis, and therapy. BTP has four Specific Aims that encompass the broad technological expertise found within the Program. Aim 1 is to develop and validate radiological diagnostic and therapeutic technologies. Aim 2 is to develop and validate optical spectroscopic and imaging technologies (Biophotonics). Aim 3 is to develop molecular and cellular technologies for translational and clinical applications. Aim 4 is to develop and validate computational methods and Artificial Intelligence (AI) techniques. Laura Marcu, PhD (biomedical engineering) and Ramsey Badawi, PhD (radiological sciences) are co-leaders for BTP. The Program’s research portfolio encompasses a wide range of technologies and computational methods, from transformative developments related to PET and CT (including the development of the world’s first total-body PET scanner), and establishing fluorescence lifetime imaging as a means for intra-operative tissue characterization, to developing novel theranostic agents for imaging and therapy, and developing robust neural networks and other Artificial Intelligence (AI) techniques to improve cancer imaging. BTP has 21 full members from three schools/colleges and seven departments at UC Davis. BTP’s total cancer relevant funding is $9.6M annual direct cost, including $8.9M in peer-reviewed and $4.6M in NCI funding. The total number of publications is 313 of which 22% are intra-programmatic, 42% inter-programmatic, 46% multi-institutional, and 15% published in high impact journals. As a strong Program with several technologies entering clinical implementation or evaluation, the UCDCCC has deployed measures to ensure technology development and clinical translation continue. This includes institutional support to maintain robust transdisciplinary fora and provide discretionary funding support to the BTP, providing its leadership the ability to support pilot projects that will continue the Program’s transformative impact.